Table 1.
Viral load linear median mixed-effects model group comparisons
Group comparisonEstimateaP valueb
CIRC0196 (Fig. 5 ) full modelc: days 42–84 after engraftment 
No Tx vs. CMV 0.39 0.228 
No Tx vs. HST 0.34 0.346 
No Tx vs. HST-NG 0.52 0.046 
CIRC0196 (Fig. 5 ) restricted modeld: days 42–56 after engraftment 
No Tx vs. CMV 0.37 0.061 
No Tx vs. HST 0.94 0.005 
No Tx vs. HST-NG 0.75 <0.001 
WWH004 (Fig. 8 ) full modelc: days 51–99 after engraftment 
No Tx vs. CMV-NG 0.36 0.504 
No Tx vs. HST-NG 0.80 0.170 
WWH004 (Fig. 8 ) restricted modeld: days 51–65 after engraftment 
No Tx vs. CMV-NG 0.26 0.603 
No Tx vs. HST-NG 0.31 0.538 
Group comparisonEstimateaP valueb
CIRC0196 (Fig. 5 ) full modelc: days 42–84 after engraftment 
No Tx vs. CMV 0.39 0.228 
No Tx vs. HST 0.34 0.346 
No Tx vs. HST-NG 0.52 0.046 
CIRC0196 (Fig. 5 ) restricted modeld: days 42–56 after engraftment 
No Tx vs. CMV 0.37 0.061 
No Tx vs. HST 0.94 0.005 
No Tx vs. HST-NG 0.75 <0.001 
WWH004 (Fig. 8 ) full modelc: days 51–99 after engraftment 
No Tx vs. CMV-NG 0.36 0.504 
No Tx vs. HST-NG 0.80 0.170 
WWH004 (Fig. 8 ) restricted modeld: days 51–65 after engraftment 
No Tx vs. CMV-NG 0.26 0.603 
No Tx vs. HST-NG 0.31 0.538 
a

Estimate comparing log10-transformed VLs between groups.

b

Adjusted for multiple comparisons using multivariate t-distribution method. Bolded P value denotes significance.

c

Modeling longitudinal VLs from peak viremia to end of study.

d

Modeling longitudinal VLs from peak viremia to point of viral escape.

or Create an Account

Close Modal
Close Modal